What's Going On With Sonnet BioTherapeutics Stock Today?
Portfolio Pulse from Vandana Singh
Sonnet BioTherapeutics Holdings Inc's shares are trading higher after the company announced that the IND for SB221, the Phase 1b/2a trial of SON-1010 in combination with Roche Holding AG's atezolizumab, has been accepted. The study will begin in the U.S. for platinum-resistant ovarian cancer. The trial will establish the maximum tolerated dose of SON-1010 with a fixed dose of atezolizumab. SONN shares are up 23.78% at $0.40 at publication Wednesday.
August 16, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sonnet BioTherapeutics' shares are trading higher after the company announced the acceptance of the IND for SB221, the Phase 1b/2a trial of SON-1010 in combination with Roche's atezolizumab.
The acceptance of the IND for SB221, the Phase 1b/2a trial of SON-1010, is a positive development for Sonnet BioTherapeutics. This could potentially lead to a new treatment for platinum-resistant ovarian cancer, which would significantly boost the company's prospects and its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Roche Holding AG's atezolizumab is being used in combination with Sonnet BioTherapeutics' SON-1010 in a Phase 1b/2a trial for platinum-resistant ovarian cancer.
While Roche's atezolizumab is being used in the trial, the news is more directly related to Sonnet BioTherapeutics. However, if the trial proves successful, it could potentially boost the profile and usage of atezolizumab, which would be positive for Roche.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50